The overall objectives of is to Improve the quality and quantity of cancer research at the University of Oklahoma Hearth Sciences Center (OUHSC), to increase NIH funding in Oklahoma through the mentoring of promising junior investigators (PJIs) and to develop support for the infrastructure for cancer research, this COBRE grant will greatly strengthen cancer research in Oklahoma and enhance the research base, infrastructure, and core capacities of the Cancer Center. The focused and structured mentoring experience that the COBRE grant supports will be a determinative influence helping PJIs achieve independent national funding. Finally, as has been seen on campus in the areas of Vision, Diabetes, Dental Sciences and Microbial Pathogenesis, the CoBRE grant will help accelerate the development of the Cancer Center as it progresses towards a submitting a competitive NCI Cancer Center Support Grant application.
The Specific Aims of this CBRE application are: 1. To mentor promising junior investigators (PJIs) In cancer research, enabling them to become independent NIH-funded investigators. Four PJIs have been selected. Each has been assigned a mentor and a co-mentor who are established cancer researchers in Oklahoma with expertise related to the PJI's project. The four PJIs have diverse but related projects that are integrated under the overall theme of "Tumor Biology: Resistance to Cancer Therapy and Mitigating Strategies." 2. To establish and develop research infrastructure to support cancer research, optimize the research environment for the PJIs, and form a core resource for the developing Stephenson Oklahoma Cancer Center. Four shared Cores will be established in this COBRE to assist the PJI projects and to serve the cancer research community in Oklahoma. 3. To foster and enhance collaborations between basic scientists and clinicians, and to facilitate translational research directed toward the development of new diagnostics and treatments for cancer.
Cancer represents a major health burden in the US. Ultimately, alleviating the burden of cancer will come from research: the generation of new ideas and, consequently, the development of novel agents. A COBRE grant will allow the Oklahoma Cancer Center to provide PJIs a focused mentoring experience to help them mature into independently-funded investigators contributing to the overall fight against cancer.
|Ramraj, Satish Kumar; Aravindan, Sheeja; Somasundaram, Dinesh Babu et al. (2016) Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease. Oncotarget 7:18605-19|
|Zhang, Zhi; Subramaniam, Sabareesh; Kale, Justin et al. (2016) BH3-in-groove dimerization initiates and helix 9 dimerization expands Bax pore assembly in membranes. EMBO J 35:208-36|
|Huang, Qingling; Schneeberger, Valentina E; Luetteke, Noreen et al. (2016) Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. Mol Cancer Ther 15:2521-2529|
|Nguyen, Charles B; Kotturi, Hari; Waris, Gulam et al. (2016) (Z)-3,5,4'-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. Cancer Res 76:4887-96|
|Corbin, Joshua M; Overcash, Ryan F; Wren, Jonathan D et al. (2016) Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer. Prostate 76:97-113|
|Srivastava, Akhil; Amreddy, Narsireddy; Babu, Anish et al. (2016) Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep 6:38541|
|Muralidharan, Ranganayaki; Babu, Anish; Amreddy, Narsireddy et al. (2016) Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology 14:47|
|Ha, Ji Hee; Ward, Jeremy D; Radhakrishnan, Rangasudhagar et al. (2016) Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via GÎ±i2, Src, and HIF1Î± signaling nexus. Oncotarget 7:37664-37679|
|Kim, Tae-Dong; Jin, Fang; Shin, Sook et al. (2016) Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. J Clin Invest 126:706-20|
|Amreddy, Narsireddy; Muralidharan, Ranganayaki; Babu, Anish et al. (2015) Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Int J Nanomedicine 10:6773-88|
Showing the most recent 10 out of 38 publications